SI-BONE Inc

SI-BONE Inc(SIBN)股票分析

$21.480

-0.079 (-0.37%)收盤時

Loading chart…
最高
21.630
開盤
21.210
成交量加權均價
21.26
成交量
469.09K
市值
512.18M
最低
20.665
成交金額
9.97M
企業價值/稅息折舊攤銷前利潤(TTM)
-64.55

SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.

AI 分析 of SI-BONE Inc (SIBN)

買進

SI-BONE Inc is a good buy right now due to its current price of $21.48, a strong RSI of 78.24 indicating momentum, and a gross margin of 79.54% which showcases effective cost management. The company has also received FDA clearance for its Onyx system, which is expected to drive future revenue growth. However, the main risk is the negative earnings per share (EPS) of -0.09 projected for the next quarter, indicating ongoing losses.

分析師評級(4)

上檔空間 +17.18%
買進
4 買進
0 持有
0 賣出
目前: 21.48
最低
23.00
平均
25.17
最高
28.00

UBS

2026-08-04

目標價

$25

買進

TD Cowen

2026-08-04

目標價

$20

買進

Truist

2026-08-04

目標價

$23

買進

UBS

2026-07-28

目標價

$24

買進

Truist

2026-07-16

目標價

$21

買進

估值指標

SI-BONE Inc(SIBN)目前預期本益比為 0.00,5 年平均預期本益比為 -18.24。

預期本益比

嚴重高估
5 年均值 P/E
-18.24
目前P/E
0.00
高估
-11.11
低估
-25.36

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
46.07
目前EV/EBITDA
-64.55
高估
388.95
低估
-296.82

預期股價營收比

合理
5 年均值 P/S
4.26
目前P/S
3.60
高估
5.71
低估
2.81

Alphio AI 對 SIBN 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%SIBN

$24.86

情境價格

基

基準

基準 · 50%SIBN

$23.43

情境價格

悲

悲觀

悲觀 · 25%SIBN

$20.99

情境價格

持有 SIBN 的大戶

P

Paradigm Capital Management, Inc.

+ 持有SIBN

-20.90%

3個月報酬率

事件時間軸

2026-09-28 (ET)

16:30:00

SI-Bone Receives FDA 510(k) Clearance for iFuse Granite Onyx System

2026-08-03 (ET)

17:00:00

Q2 Revenue of $56.0M Exceeds Consensus

17:00:00

Company Maintains FY26 Gross Margin Guidance at ~79%

2026-05-12 (ET)

16:20:00

Major Averages Finish Mixed as Semiconductor Stocks Pull Back

12:00:00

Nasdaq Declines as Semiconductor Stocks Pull Back

資訊

SIBN 常見問題 —— 由 Alphio AI 解答

SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

SI-BONE Inc is a good buy right now due to its current price of $21.48, a strong RSI of 78.24 indicating momentum, and a gross margin of 79.54% which showcases effective cost management. The company has also received FDA clearance for its Onyx system, which is expected to drive future revenue growth. However, the main risk is the negative earnings per share (EPS) of -0.09 projected for the next quarter, indicating ongoing losses.

4 analysts cover SIBN: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 25.17.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易